Satoshi Ebata

1.0k total citations · 1 hit paper
36 papers, 655 citations indexed

About

Satoshi Ebata is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Satoshi Ebata has authored 36 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pathology and Forensic Medicine, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Epidemiology. Recurrent topics in Satoshi Ebata's work include Systemic Sclerosis and Related Diseases (28 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers) and Inflammatory Myopathies and Dermatomyositis (13 papers). Satoshi Ebata is often cited by papers focused on Systemic Sclerosis and Related Diseases (28 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers) and Inflammatory Myopathies and Dermatomyositis (13 papers). Satoshi Ebata collaborates with scholars based in Japan, United States and Canada. Satoshi Ebata's co-authors include Shinichi Sato, Ayumi Yoshizaki, Takemichi Fukasawa, Asako Yoshizaki‐Ogawa, Yoshihide Asano, Shunsuke Miura, Ai Kuzumi, Koji Oba, Kazuki Matsuda and Kosuke Kashiwabara and has published in prestigious journals such as Nature Communications, The Journal of Immunology and Frontiers in Immunology.

In The Last Decade

Satoshi Ebata

33 papers receiving 643 citations

Hit Papers

Safety and efficacy of rituximab in systemic sclerosis (D... 2021 2026 2022 2024 2021 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial
    2021 142 citations Satoshi Ebata, Ayumi Yoshizaki et al. The Lancet Rheumatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Satoshi Ebata Japan 15 449 241 218 211 135 36 655
F. Storino Italy 4 542 1.2× 161 0.7× 192 0.9× 155 0.7× 200 1.5× 6 592
Ikuko Hayakawa Japan 13 366 0.8× 174 0.7× 92 0.4× 209 1.0× 123 0.9× 23 637
C.P. Denton United Kingdom 11 461 1.0× 128 0.5× 173 0.8× 160 0.8× 155 1.1× 28 620
Solène Tatibouet Canada 12 566 1.3× 226 0.9× 187 0.9× 209 1.0× 236 1.7× 16 648
Andreu Fernández‐Codina Spain 13 374 0.8× 307 1.3× 207 0.9× 128 0.6× 123 0.9× 43 710
C. Frantz France 9 266 0.6× 99 0.4× 123 0.6× 134 0.6× 98 0.7× 18 410
Yuri Masui Japan 14 230 0.5× 102 0.4× 71 0.3× 131 0.6× 119 0.9× 30 452
Wanlong Wu China 12 142 0.3× 274 1.1× 181 0.8× 104 0.5× 60 0.4× 31 475
Jasper Broen Netherlands 6 247 0.6× 80 0.3× 62 0.3× 261 1.2× 87 0.6× 10 505
Catherine Alderdice Canada 5 259 0.6× 94 0.4× 109 0.5× 135 0.6× 121 0.9× 7 470

Countries citing papers authored by Satoshi Ebata

Since Specialization
Citations

This map shows the geographic impact of Satoshi Ebata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Ebata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Ebata more than expected).

Fields of papers citing papers by Satoshi Ebata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Ebata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Ebata. The network helps show where Satoshi Ebata may publish in the future.

Co-authorship network of co-authors of Satoshi Ebata

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Ebata. A scholar is included among the top collaborators of Satoshi Ebata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Ebata. Satoshi Ebata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matsuda, Kazuki, Yang‐Yi Chen, Satoshi Ebata, et al.. (2025). Autoantibody landscape and functional role of anti-C-C motif chemokine receptor 8 autoantibodies in systemic sclerosis: post-hoc analysis of a B-cell depletion trial. Nature Communications. 16(1). 10872–10872.
2.
Kuzumi, Ai, et al.. (2025). Usefulness of rituximab for the treatment of systemic sclerosis-associated interstitial lung disease: Further analysis of the DESIRES trial. Journal of the American Academy of Dermatology. 92(6). 1402–1404. 1 indexed citations
3.
Kuzumi, Ai, Koji Oba, Satoshi Ebata, et al.. (2024). Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial. Lara D. Veeken. 64(SI). SI114–SI121. 2 indexed citations
4.
Fukasawa, Takemichi, Ayumi Yoshizaki, Satoshi Ebata, et al.. (2023). Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial. Journal of the American Academy of Dermatology. 89(2). 366–369. 27 indexed citations
5.
Matsuda, Kazuki, Kei Yamaguchi, Eriko Fukuda, et al.. (2023). Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis revealed by proteome-wide autoantibody screening. Journal of Autoimmunity. 135. 102995–102995. 8 indexed citations
6.
Kuzumi, Ai, Satoshi Ebata, Takemichi Fukasawa, et al.. (2023). Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis. JAMA Dermatology. 159(4). 374–374. 21 indexed citations
7.
Sugita, Hikaru, et al.. (2023). Polyvinyl-alcohol-based color resist for low-temperature color-filter production. Displays. 77. 102393–102393. 2 indexed citations
8.
Yoshizaki, Ayumi, Takemichi Fukasawa, Satoshi Ebata, Asako Yoshizaki‐Ogawa, & Shinichi Sato. (2022). Involvement of B cells in the development of systemic sclerosis. Frontiers in Immunology. 13. 938785–938785. 14 indexed citations
9.
Matsuda, Kazuki, Ayumi Yoshizaki, Kei Yamaguchi, et al.. (2022). Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. Frontiers in Immunology. 13. 893086–893086. 11 indexed citations
10.
Matsuda, Kazuki, Ayumi Yoshizaki, Ai Kuzumi, et al.. (2021). Development of a prediction model of treatment response in patients with cutaneous arteritis: Insights from a cohort of 33 patients. The Journal of Dermatology. 48(7). 1021–1026. 5 indexed citations
11.
Kuzumi, Ai, Ayumi Yoshizaki, Kazuki Matsuda, et al.. (2021). Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nature Communications. 12(1). 5947–5947. 57 indexed citations
12.
Ebata, Satoshi, Ayumi Yoshizaki, Koji Oba, et al.. (2021). Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. The Lancet Rheumatology. 3(7). e489–e497. 142 indexed citations breakdown →
13.
Kuzumi, Ai, Ayumi Yoshizaki, Satoshi Ebata, et al.. (2021). Serum TARC Levels in Patients with Systemic Sclerosis: Clinical Association with Interstitial Lung Disease. Journal of Clinical Medicine. 10(4). 660–660. 4 indexed citations
14.
15.
Ebata, Satoshi, Ayumi Yoshizaki, Takemichi Fukasawa, et al.. (2020). Rapid decrease of serum surfactant protein‐D levels predicts the reactivity of rituximab therapy in systemic sclerosis‐associated interstitial lung disease. The Journal of Dermatology. 47(7). 796–800. 5 indexed citations
16.
Matsuda, Kazuki, Ayumi Yoshizaki, Ai Kuzumi, et al.. (2019). Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. Arthritis Research & Therapy. 21(1). 129–129. 26 indexed citations
17.
Kuzumi, Ai, Ayumi Yoshizaki, Takemichi Fukasawa, et al.. (2018). Serum interleukin‐34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease. The Journal of Dermatology. 45(10). 1216–1220. 20 indexed citations
18.
Yoshizaki, Ayumi, Takemichi Fukasawa, Satoshi Ebata, et al.. (2018). Rapid alteration of serum interleukin‐6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis‐associated interstitial lung disease. The Journal of Dermatology. 45(10). 1221–1224. 7 indexed citations
19.
Yoshizaki, Ayumi, Takashi Taniguchi, Ryosuke Saigusa, et al.. (2015). Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. Annals of the Rheumatic Diseases. 75(10). 1858–1865. 15 indexed citations
20.
Yamamoto, Masafumi, Kiyoshi Murata, Hiroyuki Ishii, et al.. (2001). 193 SLR system based on COMA/acryl hybrid system. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 4345. 680–680.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Storino Breakdown of academic impact, for papers by Ikuko Hayakawa Breakdown of academic impact, for papers by C.P. Denton Breakdown of academic impact, for papers by Solène Tatibouet Breakdown of academic impact, for papers by Andreu Fernández‐Codina Breakdown of academic impact, for papers by C. Frantz Breakdown of academic impact, for papers by Yuri Masui Breakdown of academic impact, for papers by Wanlong Wu Breakdown of academic impact, for papers by Jasper Broen Breakdown of academic impact, for papers by Catherine Alderdice
Rankless by CCL
2026